Boston Scientific Seeks To Defend Rapid-Exchange Patents In U.S., Abroad
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific is seeking to defend the intellectual property gained through its $2.1 bil. Schneider buy in 1998 by filing suit against Medtronic claiming infringement of a rapid-exchange catheter patent.
You may also be interested in...
Medtronic Rapid Exchange Stent Systems Require License For U.S. Marketing
Medtronic would need to pursue a license agreement with Boston Scientific in order to keep its rapid exchange coronary stent systems on the U.S. market, following an adverse arbitration panel ruling July 18.
Medtronic Rapid Exchange Stent Systems Require License For U.S. Marketing
Medtronic would need to pursue a license agreement with Boston Scientific in order to keep its rapid exchange coronary stent systems on the U.S. market, following an adverse arbitration panel ruling July 18.
Boston Scientific Stent Suit Seeks Injunctive Relief From J&J Market Entry
Boston Scientific's stent patent suit against Johnson & Johnson's Cordis unit follows by ten days an agreement between J&J and Guidant to co-develop balloon dilatation catheters on a rapid-exchange platform.